These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8440570)

  • 41. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New possibilities for diagnosis and treatment of osteoporosis.
    Miller PD
    Int J Fertil Womens Med; 2001; 46(4):215-21. PubMed ID: 11563832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Osteoporosis-induced fractures. Bisphosphonates lower risk also in the hip].
    MMW Fortschr Med; 2000 Jul; 142(30):52-3. PubMed ID: 10955025
    [No Abstract]   [Full Text] [Related]  

  • 44. The effect of different doses of calcitonin on bone mineral density and fracture risk in postmenopausal osteoporosis.
    Hizmetli S; Elden H; Kaptanoglu E; Nacitarhan V; Kocagil S
    Int J Clin Pract; 1998 Oct; 52(7):453-5. PubMed ID: 10622084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Estrogen treatment for prevention and therapy of osteoporosis].
    von Werder K
    Fortschr Med; 1997 Oct; 115(29):44-9. PubMed ID: 9445834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Teriparatide (human recombinant 1-34 parathyroid hormone)--a new treatment regimen for severe osteoporosis].
    Vestergaard P; Nielsen LR; Mosekilde L
    Ugeskr Laeger; 2004 Aug; 166(32):2653-5. PubMed ID: 15347166
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of early menopause on bone mineral density and fractures.
    Gallagher JC
    Menopause; 2007; 14(3 Pt 2):567-71. PubMed ID: 17476146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Calcium and vitamin D in the prevention and treatment of osteoporosis.
    Orcel P
    Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):70S-74S. PubMed ID: 9273942
    [No Abstract]   [Full Text] [Related]  

  • 49. Estrogens and osteoporosis.
    Ribot C; Trémollières F
    Rev Rhum Engl Ed; 1998 Nov; 65(11):641-8. PubMed ID: 9850533
    [No Abstract]   [Full Text] [Related]  

  • 50. Osteoporosis screening: time to take responsibility.
    Mazanec D
    Arch Intern Med; 2004 May; 164(10):1047-8. PubMed ID: 15159261
    [No Abstract]   [Full Text] [Related]  

  • 51. Beyond bone mineral density: several factors define bone health.
    Ruhl C
    Nurs Womens Health; 2008 Jun; 12(3):249-51. PubMed ID: 18557856
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
    Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
    Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pathophysiology of osteoporosis and bone density determination].
    Dambacher MA; Haas HG; Rüegsegger P
    Internist (Berl); 1991 Feb; 32(2):63-9. PubMed ID: 2032790
    [No Abstract]   [Full Text] [Related]  

  • 56. [Indications for measuring bone density].
    Haberkamp M; Allolio B
    Med Klin (Munich); 1992 Mar; 87(3):131-8. PubMed ID: 1579090
    [No Abstract]   [Full Text] [Related]  

  • 57. Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study.
    Ringe JD; Setnikar I
    Rheumatol Int; 2002 May; 22(1):27-32. PubMed ID: 12120908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The osteoprotective effect of ovarian hormones].
    Hesch RD
    Wien Med Wochenschr; 1992; 142(5-6):127-9. PubMed ID: 1615682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of osteoporosis with estrogen].
    Mizunuma H
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():397-403. PubMed ID: 15035159
    [No Abstract]   [Full Text] [Related]  

  • 60. [The new concept of osteoporosis. Early diagnosis, prevention and therapy are possible today].
    Hesch RD; Harms H; Rittinghaus EF; Brabant G
    Fortschr Med; 1990 Apr; 108(11):219-21. PubMed ID: 2358288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.